Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Non-Current Liabilities (2016 - 2025)

Dare Bioscience's Other Non-Current Liabilities history spans 10 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 13.51% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, up 13.51%, while the annual FY2025 figure was $5.4 million, 13.51% up from the prior year.
  • Other Non-Current Liabilities reached $5.4 million in Q4 2025 per DARE's latest filing, up from $5.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.4 million in Q4 2025 to a low of $1.0 million in Q2 2021.
  • Average Other Non-Current Liabilities over 4 years is $4.3 million, with a median of $4.6 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: changed 0.0% in 2021, then grew 21.26% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $1.0 million in 2021, then skyrocketed by 291.37% to $3.9 million in 2023, then increased by 21.26% to $4.7 million in 2024, then increased by 13.51% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Other Non-Current Liabilities are $5.4 million (Q4 2025), $5.2 million (Q3 2025), and $4.9 million (Q2 2025).